SAN DIEGO, Sept. 10 /PRNewswire/ — Orexigen® Therapeutics,
OREX), a biopharmaceutical company focused on the treatment of
obesity, today announced that the Company will be speaking at the
Rodman & Renshaw Annual Global Investment Conference.
The details are as follows:
Date: September 14, 2010
Time: 5:45pm (EDT)
Location: New York Palace Hotel
Speaker: Mark Booth, Chief Commercial Officer
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company
focused on the treatment of obesity. The Company has filed an NDA
with the FDA for its lead investigational product, Contrave®.
The Company’s second product, Empatic™, has completed
Phase 2 clinical development. Each product candidate is
designed to act on a specific group of neurons in the central
nervous system with the goal of achieving appetite suppression and
sustained weight loss, through combination therapeutic approaches.
Further information about the Company can be found at